Rova-T

ASCO 2022 – the spirit of Rova-T struggles to live on
EP Vantage
Tue, 06/7/22 - 10:19 am
ASCO 2022
Rova-T
AbbVie
Harpoon Therapeutics
Amgen
Boehringer Ingelheim
Rova-T: the story of AbbVie’s multi-billion dollar failure
Pharmaforum
Wed, 09/4/19 - 10:12 am
AbbVie
lung cancer
M&A
Stemcentrx
Rova-T
$5.8B for Nothing: AbbVie Shelves Stemcentryx Drug After Latest Flop
Xconomy
Thu, 08/29/19 - 10:33 am
AbbVie
Stemcentryx
Rova-T
Remember that mega-blockbuster valuation AbbVie assigned to Rova-T? It’s starting to vanish — quietly
Endpoints
Sat, 01/5/19 - 01:37 pm
AbbVie
Rova-T
AbbVie suffers fresh setback with lung cancer drug Rova-T
Pharmaforum
Thu, 12/6/18 - 12:33 pm
AbbVie
Rova-T
lung cancer
advanced SCLC
Pharma's 2 Biggest Setbacks in 2018
Motley Fool
Sun, 07/1/18 - 11:29 am
AbbVie
Celgene
Rova-T
ozanimod
After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr
Endpoints
Mon, 06/25/18 - 12:45 pm
AbbVie
Rova-T
solid tumors
Calibr
CAR-T
#ASCO18: AbbVie convinces one top analyst that its $6B ‘megablockbuster’ Rova-T is worthless
Endpoints
Tue, 06/5/18 - 12:09 pm
AbbVie
Rova-T
ASCO 2018
antibody-drug conjugate
When Will They Learn? 4 Huge Biotech Blowups
Motley Fool
Thu, 03/29/18 - 09:24 pm
biotech
AstraZeneca
ZS-9
drug manufacturing
Alexion
Synageva
Merck
Cubist Pharmaceuticals
AbbVie
Rova-T
Stemcentrx
3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News
GoinPharma
Sun, 03/25/18 - 11:24 am
biotech
FDA
Azedra
Progenics Pharmaceuticals
AbbVie
Rova-T
PharmaMar
Is AbbVie 'Unraveling' In Solid Tumor Market After Drug Misstep?
Investors Business Daily
Sat, 03/24/18 - 09:10 am
AbbVie
solid tumors
Rova-T
lung cancer
Is It Game Over for AbbVie's Promising Cancer Drug?
Motley Fool
Thu, 03/22/18 - 10:21 pm
Rova-T
AbbVie
lung cancer
AbbVie says not seeking accelerated approval for lung cancer drug
Yahoo/Reuters
Thu, 03/22/18 - 09:07 am
AbbVie
drug approvals
accelerated approvals
lung cancer
Rova-T
These 3 Drugs Are Critical to AbbVie's Success
Motley Fool
Mon, 02/12/18 - 09:10 am
AbbVie
Rova-T
Upadacitinib
risankizumab
5 Biggest New Drugs of 2018
Motley Fool
Sun, 01/7/18 - 12:35 pm
Gilead Sciences
Bictegravir/F/TAF
Novo Nordisk
semaglutide
Ozempic
Incyte
epacadostat
AbbVie
Rova-T
Celgene
ozanimod
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
Sun, 12/17/17 - 11:47 am
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Sun, 07/23/17 - 11:47 am
Biogen
aducanumab
JNJ
apalutamide
Eli Lilly
abemaciclib
AbbVie
Rova-T
Celgene
ozanimod
How AbbVie Is Attacking Tumors at Their Roots
Motley Fool
Wed, 03/29/17 - 09:06 am
AbbVie
solid tumors
cancer
stem cells
Stemcentrx
Rova-T
How Late-Stage Asset Rova-T Could Become a Leading Therapy
Market Realist
Fri, 08/26/16 - 09:56 am
Rova-T
AbbVie
small cell lung cancer
AbbVie Inc: New Drugs May Overcome Humira Loss
Bidness, ETC
Mon, 08/1/16 - 03:56 pm
AbbVie
Humira
Rova-T
Venclexta
Imbruvica
Viekira Pak

Pages